DaVita Brings New Clinical Research to ASN Kidney Week 2026, Advancing Evidence for the Next Era of Kidney Care

Steven Brunelli, MD, group vice president of research for DaVita

“Kidney care is experiencing more therapeutic and treatment innovation than we've seen in decades. But innovation only matters if it can be translated into better care for patients.”

Steven Brunelli, MD, group vice president of research for DaVita

“Our research helps clinicians evaluate emerging therapies through the lens of real-world practice, providing evidence that can help support care decisions today.”

Steven Brunelli, MD, group vice president of research for DaVita

“Our findings help clarify an important misconception regarding albumin and expanded HD. The data suggest this therapy can benefit a broad range of patients while preserving albumin levels, helping nephrologists and patients make more informed treatment decisions.”

Jeff Giullian, MD, chief medical officer for DaVita

“Middle molecule clearance is quickly reshaping what's possible in U.S. dialysis care.”

Jeff Giullian, MD, chief medical officer for DaVita

“At the same time, progress in kidney care is being driven by innovations across the care journey, from early intervention and home therapies to patient engagement and treatment support. Together, these research efforts are helping create a more personalized treatment journey for patients.”